What is Big Think?  

We are Big Idea Hunters…

We live in a time of information abundance, which far too many of us see as information overload. With the sum total of human knowledge, past and present, at our fingertips, we’re faced with a crisis of attention: which ideas should we engage with, and why? Big Think is an evolving roadmap to the best thinking on the planet — the ideas that can help you think flexibly and act decisively in a multivariate world.

A word about Big Ideas and Themes — The architecture of Big Think

Big ideas are lenses for envisioning the future. Every article and video on bigthink.com and on our learning platforms is based on an emerging “big idea” that is significant, widely relevant, and actionable. We’re sifting the noise for the questions and insights that have the power to change all of our lives, for decades to come. For example, reverse-engineering is a big idea in that the concept is increasingly useful across multiple disciplines, from education to nanotechnology.

Themes are the seven broad umbrellas under which we organize the hundreds of big ideas that populate Big Think. They include New World Order, Earth and Beyond, 21st Century Living, Going Mental, Extreme Biology, Power and Influence, and Inventing the Future.

Big Think Features:

12,000+ Expert Videos


Browse videos featuring experts across a wide range of disciplines, from personal health to business leadership to neuroscience.

Watch videos

World Renowned Bloggers


Big Think’s contributors offer expert analysis of the big ideas behind the news.

Go to blogs

Big Think Edge


Big Think’s Edge learning platform for career mentorship and professional development provides engaging and actionable courses delivered by the people who are shaping our future.

Find out more

23andMe and the Democratization of Health Information

November 25, 2013, 4:58 PM

The FDA has told the DNA analysis company 23andMe that it must "immediately discontinue" the marketing of its signature product, the $99 Saliva Collection Kit and Personal Genome Service, or PGS, due to a lack of "marketing clearance or approval."

The PGS provides people "health reports on 254 diseases and conditions." 

In a warning letter made public today the FDA described its concern about "the potential health consequences that could result from false positive or false negative assessments." In the case of a false positive report, a patient might undergo surgery or other "morbidity-inducing actions," the agency wrote, "while a false negative could result in a failure to recognize an actual risk that may exist."

What's the Big Idea?

The FDA letter notes its "long history of working with companies to help them come into compliance with the FD&C Act." Statements from 23andMe indicate the company's desire to come into compliance. We don't know how this particular matter will be resolved, but we do know this issue is not going away. In fact, Bloomberg notes that genetic tests may become a $25 billion annual market in the U.S. within a decade

The company 23andMe,  notes at Slate, is part of "a broader movement toward the democratization of health information" that the government can't stop. This incident, therefore, 

highlights the tension between the paternalistic medical establishment that arose to deal with the dangers of 19th-century quack medicine, and a “techno-populist” element of American society pioneering personal health assessment and decision-making by leveraging new information technologies. Caught between them is the general public, which trusts institutions but is obviously intrigued by the offerings of consumer medicine, as judged by units sold of 23andMe's kits.

In the video below, Anne Wojcicki, co-founder of 23andMe, tells Big Think that people should have access to anything that is fundamentally theirs.

Watch the video here:




23andMe and the Democratiza...

Newsletter: Share: